First Shoulder Arthroplasty Surgeries Using Stryker’s Blueprint® Mixed Reality Guidance System Completed in Europe

Blueprint Mixed Reality Guidance System offers shoulder arthroplasty surgeons a new tool to execute their pre-operative plan

Blueprint Mixed Reality (MR) Guidance

Stryker (NYSE:SYK), a global leader in medical technologies, today announced that the first shoulder arthroplasty surgeries using Blueprint Mixed Reality (MR) Guidance in Europe have been successfully completed by Professor Julien Berhouet, MD, PhD, CHRU Tours Hospital, France, and Dr. Lionel Neyton, MD, orthopaedic shoulder surgeon at Centre Orthopédique Santy and Hôpital Privé Jean Mermoz in Lyon, France.

Professor Berhouet Comments

“It’s exciting to be one of the first two hospitals in Europe to use Stryker’s Mixed Reality Guidance System,” said Professor Berhouet. “I am also pleased to be leading a pilot study to investigate the safety and effectiveness of this new technology, alongside three other centres in France.”

Dr. Lionel Neyton Added

“The Blueprint Mixed Reality System allows me to tailor my shoulder joint replacement procedures to the unique needs and anatomy of my patients,” Dr. Neyton added.

Designed in collaboration with a team of world-class surgeons, the Blueprint Mixed Reality Guidance System combines Stryker’s innovative software with the Microsoft HoloLens 2 headset, allowing the surgeon to track the position and orientation of surgical instrumentation in the physical environment. Blueprint Mixed Reality Guidance System allows surgeons and their instruments to be ‘guided’ by 3D images and guidance widgets, which can be displayed on the patient and in the surgeon’s line of sight without disrupting normal workflow. The MR Guidance system received a CE mark at the end of 2023 and the first surgeries globally were performed in the U.S. and Canada in December 2023.

Markus Ochs, VP and General Manager of Stryker’s European Trauma & Extremities Division

“This latest tool builds upon a decade of Blueprint’s presence in Europe, and we continue innovating to ensure the platform has the potential to further benefit surgeons and patients alike.”

To learn more about Blueprint and Mixed Reality, visit stryker.com.

SourceStryker

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.